Gouvernance Gan & Lee Pharmaceuticals.

Actions

603087

CNE100003ZH1

Produits pharmaceutiques

Cours en clôture Shanghai S.E. 18/05/2026 Varia. 5j. Varia. 1 janv.
54,62 CNY -3,40 % Graphique intraday de Gan & Lee Pharmaceuticals. -9,30 % -19,76 %

Comité Exécutif: Gan & Lee Pharmaceuticals.

Dirigeant
Fonctions occupéesDepuis
Wei Chen

Wei Chen

46 ans

Chief Executive Officer 30/05/2025
Rong Zou

Rong Zou

43 ans

Corporate Secretary 29/12/2017
Qi Wang

Qi Wang

44 ans

Director of Finance/CFO 09/03/2026
Ting Jia

Ting Jia

Chief Tech/Sci/R&D Officer 09/03/2026

Composition du Conseil d'Administration: Gan & Lee Pharmaceuticals.

Administrateur
ComitésDepuis
Wei Chen

Wei Chen

46 ans

Nominating Committee 30/05/2025
Zeng Yi Chang

Zeng Yi Chang

61 ans

Audit Committee 19/05/2022
Compensation Committee 19/05/2022
Nominating Committee 19/05/2022
Hong Pin Du

Hong Pin Du

53 ans

Audit Committee 20/05/2025
Compensation Committee Chair 10/09/2020
Zhong Ru Gan

Zhong Ru Gan

78 ans

Audit Committee 29/05/2012
Compensation Committee 29/05/2012
Wei Qiang Song

Wei Qiang Song

44 ans

Audit Committee 15/09/2015
Kai Du

Kai Du

49 ans

Nominating Committee 01/01/2010
Jiao Jiao

Jiao Jiao

38 ans

Director/Board Member 18/03/2021
Fu Ming Xu

Fu Ming Xu

41 ans

Director/Board Member 17/11/2025

Anciens Dirigeants et Administrateurs: Gan & Lee Pharmaceuticals.

Insider
Fonctions occupées
DepuisJusqu'au
Li Zhou
Li Zhou
Director of Finance/CFO 31/12/2025 09/03/2026
Corporate Officer/Principal 01/10/2019 31/12/2025
Cheng Sun
Cheng Sun
Director of Finance/CFO 20/07/2020 31/12/2025
Guo Jun Zheng
Guo Jun Zheng
Director/Board Member 26/04/2019 20/05/2025
Independent Dir/Board Member 26/04/2019 20/05/2025
Yan Qing He
Yan Qing He
Director/Board Member 26/04/2019 20/05/2025
Independent Dir/Board Member 26/04/2019 20/05/2025
Yi Wang
Yi Wang
Director/Board Member 18/03/2021 08/11/2024
Corporate Officer/Principal 01/01/2018 08/11/2024
Lei Yin
Lei Yin
Director/Board Member 18/03/2021 17/05/2024
Yan Sun
Yan Sun
Director/Board Member 15/09/2015 18/05/2022
Independent Dir/Board Member 15/09/2015 18/05/2022
Da Mei Wang
Da Mei Wang
Director/Board Member 01/01/2005 15/08/2021
Corporate Officer/Principal 01/01/2012 21/07/2020
Pu Yang
Pu Yang
Director/Board Member 26/04/2019 18/03/2021
Yan Ling Cao
Yan Ling Cao
Director/Board Member 01/04/2019 02/03/2021
Wing Yu Leung
Wing Yu Leung
Director/Board Member 01/03/2010 01/03/2021
Jun Jun Ning
Jun Jun Ning
Director of Finance/CFO 26/08/2019 21/07/2020
Jin Wook Suk
Jin Wook Suk
Director/Board Member 01/09/2011 01/09/2019
Ying Zhang
Ying Zhang
Director/Board Member - 26/04/2019
Dan Xu Liu
Dan Xu Liu
Director/Board Member - 26/04/2019
Bing Zhou
Bing Zhou
Director/Board Member - 26/04/2019
Independent Dir/Board Member - 26/04/2019
Jun Hua Jiang
Jun Hua Jiang
Director/Board Member - 26/04/2019
Independent Dir/Board Member - 26/04/2019
Boyu Zhong
Boyu Zhong
Corporate Officer/Principal 01/06/2016 01/12/2017
Hui Zou
Hui Zou
Chief Tech/Sci/R&D Officer - 28/02/2017
Yi Rao
Yi Rao
Director/Board Member - 15/09/2015
Independent Dir/Board Member - 15/09/2015
Yi Ru Gan
Yi Ru Gan
Director/Board Member 17/06/1998 15/09/2015
Founder 17/06/1998 15/09/2015
Jia Xin Wang
Jia Xin Wang
Director/Board Member 26/04/2019 -
Wei Wang
Wei Wang
Corporate Officer/Principal 01/11/2006 01/12/2007
Tao Zhang
Tao Zhang
Chairman 10/09/2021 -
Sales & Marketing 01/01/2005 10/09/2021
Jin Hui Yang
Jin Hui Yang
Comptroller/Controller/Auditor 01/01/2002 -
Chairman 26/04/2019 -
Compliance Officer 01/01/2002 -
Xi Ru Gan
Xi Ru Gan
Founder 17/06/1998 -
Ming Wang
Ming Wang
Chief Operating Officer - -
President - -

Distribution de l'Âge des Dirigeants

Parité Homme Femme

Homme11
Femme2

Dont comité exécutif

Homme3
Femme1

Dont Administrateurs

Homme7
Femme1
Logo Gan & Lee Pharmaceuticals.
Gan & Lee Pharmaceuticals est une société basée en Chine qui se consacre principalement à la recherche et au développement, à la production et à la vente d'API et d'injections d'analogues de l'insuline. Les principaux produits de la société comprennent l'insuline glargine injectable Changxiulin, l'insuline lispro injectable Suxiulin, l'insuline recombinante zinc lispro injectable mixte (25R) Suxiulin 25, l'insuline Aspart injectable Ruixilin, l'insuline Aspart 30 injectable Ruixilin30, l'insuline humaine mixte injectable Protamine (30R) Puxilin30 et de nombreux autres analogues de l'insuline et variétés d'insuline humaine, couvrant trois segments de marché fonctionnels : l'insuline à action prolongée, l'insuline à action rapide et l'insuline pré-mélangée.
Employés
5 309

Départs de Personnes Clées

Tao Zhang
-
Tao Zhang

Chairman

10/09/2021 -

Jin Hui Yang
-
Jin Hui Yang

Chairman

26/04/2019 -

🔇